PT3436019T - (1s,4s)-4-(2-(((3s,4r)-3-fluorotetra-hidro-2h-piran-4- il)amino)-8-((2,4,6-triclorofenil)amino)-9h-purin-9-il)-1- metilciclo-hexano-1-carboxamida e métodos de utilização dos mesmos - Google Patents

(1s,4s)-4-(2-(((3s,4r)-3-fluorotetra-hidro-2h-piran-4- il)amino)-8-((2,4,6-triclorofenil)amino)-9h-purin-9-il)-1- metilciclo-hexano-1-carboxamida e métodos de utilização dos mesmos

Info

Publication number
PT3436019T
PT3436019T PT177767431T PT17776743T PT3436019T PT 3436019 T PT3436019 T PT 3436019T PT 177767431 T PT177767431 T PT 177767431T PT 17776743 T PT17776743 T PT 17776743T PT 3436019 T PT3436019 T PT 3436019T
Authority
PT
Portugal
Prior art keywords
amino
fluorotetrahydro
purin
trichlorophenyl
methylcyclohexane
Prior art date
Application number
PT177767431T
Other languages
English (en)
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of PT3436019T publication Critical patent/PT3436019T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT177767431T 2016-04-01 2017-03-31 (1s,4s)-4-(2-(((3s,4r)-3-fluorotetra-hidro-2h-piran-4- il)amino)-8-((2,4,6-triclorofenil)amino)-9h-purin-9-il)-1- metilciclo-hexano-1-carboxamida e métodos de utilização dos mesmos PT3436019T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662317468P 2016-04-01 2016-04-01

Publications (1)

Publication Number Publication Date
PT3436019T true PT3436019T (pt) 2021-11-04

Family

ID=59960229

Family Applications (1)

Application Number Title Priority Date Filing Date
PT177767431T PT3436019T (pt) 2016-04-01 2017-03-31 (1s,4s)-4-(2-(((3s,4r)-3-fluorotetra-hidro-2h-piran-4- il)amino)-8-((2,4,6-triclorofenil)amino)-9h-purin-9-il)-1- metilciclo-hexano-1-carboxamida e métodos de utilização dos mesmos

Country Status (19)

Country Link
US (2) US10047090B2 (pt)
EP (2) EP3436019B1 (pt)
JP (1) JP6995058B2 (pt)
CN (1) CN109819649B (pt)
AU (1) AU2017240050B2 (pt)
CA (1) CA3019105A1 (pt)
CY (1) CY1124677T1 (pt)
DK (1) DK3436019T3 (pt)
ES (1) ES2895419T3 (pt)
HR (1) HRP20211546T1 (pt)
HU (1) HUE056631T2 (pt)
LT (1) LT3436019T (pt)
MX (1) MX379439B (pt)
PL (1) PL3436019T3 (pt)
PT (1) PT3436019T (pt)
RS (1) RS62496B1 (pt)
SI (1) SI3436019T1 (pt)
SM (1) SMT202100604T1 (pt)
WO (1) WO2017173218A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3204386T3 (da) 2014-10-06 2021-05-25 Signal Pharm Llc Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed
US10576085B2 (en) * 2016-04-01 2020-03-03 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
WO2017222819A2 (en) 2016-06-21 2017-12-28 Teva Pharmaceuticals International Gmbh Solid state forms of ixazomib citrate
EP3692041A1 (en) * 2017-10-04 2020-08-12 Celgene Corporation Processes for the preparation of cis-4 [2-{(3s.4r)-3-fluorooxan-4-yl]amino)-8-(2,4,6-trichloroanilino)-9h-purin-9-yl]-1-methylcyclohexane-1-carboxamide
MX2020003620A (es) 2017-10-04 2020-10-28 Celgene Corp Composiciones y métodos para usar cis-4-[2-{[(3s,4r)-3-fluorooxan- 4-il]amino}-8-(2,4,6-tricloroanilino)-9h-purin-9-il]-1-etilcicloh exano-1-carboxamida.
AU2019284472B2 (en) 2018-06-11 2024-05-30 Amgen Inc. KRAS G12C inhibitors for treating cancer
EP3972973A1 (en) 2019-05-21 2022-03-30 Amgen Inc. Solid state forms
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
EP4237431A1 (en) * 2020-12-15 2023-09-06 Centre National de la Recherche Scientifique Sqstm1 and its use in cancer therapy

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするdna
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
FI109088B (fi) 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7759342B2 (en) 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
WO2007062338A2 (en) 2005-11-18 2007-05-31 Astrazeneca Ab Solid formulations
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
NZ576347A (en) 2006-10-27 2011-10-28 Signal Pharm Llc Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith
DK2279731T3 (da) 2008-04-23 2013-03-18 Farmasierra Mfg S L Forbedret farmaceutisk sammensætning, som indeholder ibuprofen og codein
WO2011071491A1 (en) 2009-12-09 2011-06-16 Signal Pharmaceuticals, Llc Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2, 4, 6- trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol
US8603527B2 (en) * 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
US8680076B2 (en) * 2010-10-25 2014-03-25 Signal Pharmaceuticals, Llc Methods of treatment, improvement and prevention using haloaryl substituted aminopurines
US9466042B2 (en) 2012-01-24 2016-10-11 International Business Machines Corporation Facilitating the design of information technology solutions
WO2014172616A2 (en) 2013-04-18 2014-10-23 President And Fellows Of Harvard College Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
DK3204386T3 (da) * 2014-10-06 2021-05-25 Signal Pharm Llc Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed
US10576085B2 (en) 2016-04-01 2020-03-03 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith

Also Published As

Publication number Publication date
CN109819649B (zh) 2023-02-28
EP3436019B1 (en) 2021-07-28
ES2895419T3 (es) 2022-02-21
HRP20211546T1 (hr) 2022-01-07
SI3436019T1 (sl) 2021-12-31
US20180362529A1 (en) 2018-12-20
EP3845536A1 (en) 2021-07-07
US10513519B2 (en) 2019-12-24
PL3436019T3 (pl) 2022-01-10
EP3436019A1 (en) 2019-02-06
DK3436019T3 (da) 2021-10-11
EP3436019A4 (en) 2019-08-28
US10047090B2 (en) 2018-08-14
JP2019515889A (ja) 2019-06-13
HUE056631T2 (hu) 2022-02-28
MX2018011970A (es) 2019-05-20
US20170283418A1 (en) 2017-10-05
RS62496B1 (sr) 2021-11-30
SMT202100604T1 (it) 2021-11-12
CA3019105A1 (en) 2017-10-05
CN109819649A (zh) 2019-05-28
CY1124677T1 (el) 2022-07-22
AU2017240050A1 (en) 2018-10-11
LT3436019T (lt) 2021-10-25
MX379439B (es) 2025-03-10
JP6995058B2 (ja) 2022-02-21
WO2017173218A1 (en) 2017-10-05
AU2017240050B2 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
ES3066530T3 (en) Pd-l1-specific antibodies and methods of using the same
ZA201903932B (en) Imidazopyrazine inhibitors of bruton's tyrosine kinase
SI3436019T1 (sl) (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-piran-4-il)amino)-8-((2,4, 6-triklorofenil)amino)-9h-purin-9-il)-1-metilcikloheksane-1-karboksamid in metode uporabe
EP3558587A4 (en) ABRASIVE ARTICLE AND ITS MANUFACTURING PROCESS
EP3519137A4 (en) ABRASIVE ARTICLES AND METHOD FOR THE PRODUCTION THEREOF
SG11202002947TA (en) Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same
ZA201805439B (en) Bruton's tyrosine kinase inhibitors
LT3283136T (lt) Hidrofilinės dangos ir jų sudarymo būdai
IL259862B (en) Inhibitors of proton tyrosine kinase and methods of using them
SI3377495T1 (sl) 2-fenil-3,4-dehidropirolo(2,1-F)(1,2,4)triazinonski derivati kot zaviralci fosfodiesteraze in uporaba le-teh
ZA201902325B (en) 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
EP3651606A4 (en) PRECIOUS STONE COATINGS AND RELATED MANUFACTURING AND USE PROCEDURES
PT3258960T (pt) Proteínas imunoprotetoras de leptospira e métodos de identificação e sua utilização
ZA201901593B (en) An interchangeable jewelry linking system and clasps thereof
ZA201608720B (en) Thermobaric nonel and preparation method thereof
ZA201901505B (en) Phenylalanine-free protein for the treatment of pku
ZA201903032B (en) Nail plater apparatus and related methods
GB201607979D0 (en) Monomeric proteins and uses thereof
ZA201903845B (en) Fgfr4 inhibitor and preparation method and use thereof
SI3408264T1 (sl) Nilotinibijev dinitrat (V) in njegove kristalne oblike
GB201622441D0 (en) Abrasive article and method of use
IL254205B (en) Reagents for the acylation of amino acids and methods for their use
HK40034727A (en) Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
HK40030377A (en) Gemstone coatings and methods of making and using the same
GB201721869D0 (en) The system of identification and positioning of internet of things